Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Jun 4, 2019
Dr. Jean-Marc Steens, Chief Medical Officer, Abivax reports on clinical results that continue to show advances in the chronic treatment and maintenance of moderate to severe ulcerative colitis using a new small molecule ABX464 in an oral treatment and potential applications for other inflammatory and neurological diseases.
Jean-Marc also explains how another molecule ABX196 is being tested to determine if it might increase the outcome of treatments for hepatocellular carcinoma, the most common liver cancer, in conjunction with Opdivo a checkpoint inhibitor that is being developed with Scripps Research, University of Chicago and BYU.
#ulcerativecolitis